Drugs / MIBENRATIDE
MIBENRATIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01809353 | Jul 2013 → Sep 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01902550 | Jul → Oct 2013 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01798745 | Nov 2014 → Dec 2015 | heart failure | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIBENRATIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297617 ↗ |
| Known as | JNJ-54452840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01902550 ↗ |
| Known as | Mibenratida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297617 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297617 ↗ |
| Route | Intravenous | “Once daily intravenous injection(s) (medication is injected into a vein)” NCT01798745 ↗ |